Healio

Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk

Please provide your email address to receive an email when new articles are posted on . The authors evaluated psoriasis patients’ risks for developing psoriatic arthritis when treated with interleukin ...
The Reporter

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA(R) (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with ...

SPRING HOUSE, Pa., June 2, 2021 /PRNewswire/ — Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA (R) (guselkumab), ...
Delaware County Daily Times

New Phase 3 Data Show First-in-Class TREMFYA(R) (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis ...

In addition, results showed 56 percent of TREMFYA q4w patients and 55 percent of TREMFYA q8w patients achieved at least 50 percent improvement in ACR score (utilizing NRI). 2 Among patients who had ...